Latest News

FDA approval expands teclistamab plus daratumumab significantly improved survival in the MajesTEC-3 trial.

Meta-analysis finds insulin efsitora provides similar glycemic control with superior hemoglobin A1C reduction at 52 weeks and lower total weekly insulin dose, while maintaining an acceptable safety profile.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

Tanika Kelly, PhD, MPH, discusses her study finding that greater chronic kidney disease (CKD) severity significantly increases the risk of cognitive impairment, with important implications for how pharmacists counsel and support these patients.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.

New research links long COVID taste loss to impaired sweet-bitter-umami signaling, guiding pharmacists on nutrition risks and emerging therapies.

Long-term care pharmacies optimize medication, vaccines, and safer therapies to boost patient care, cut risks, and navigate Medicare barriers.

RSV vaccines cut hospitalization risk—and may lower dementia risk.

Lomitapide demonstrated substantial LDL cholesterol reductions in a pivotal trial.

Launching sustainable, effective CGT programs requires a road map for strategy, operations, access, finance, quality, and pharmacy.

Milsaperidone is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia in adults.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Pegvaliase becomes the only enzyme substitution therapy approved to reduce blood phenylalanine concentrations in patients with phenylketonuria.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

Michael Snyder, MD, of FuturHealth breaks down the patient safety risks of compounded glucagon-like peptide-1 (GLP-1) products and why structured care is essential as demand for these medications continues to surge.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

Oral bacteria like Fusobacterium nucleatum may fuel breast cancer—here's what pharmacists should know about periodontal health and genetic risk.

FDA priority review of rusfertide signals a new PV option, cutting phlebotomy reliance and improving hematocrit control, with pharmacists guiding injections and safety.